Skip to main content
Premium Trial:

Request an Annual Quote

BTIG Initiates Coverage of LumiraDx With Buy Rating

NEW YORK ─ Investment bank BTIG on Wednesday initiated coverage of point-of-care testing company LumiraDx with a Buy rating and a price target of $12 on its shares.

BTIG expects that over time, LumiraDx will be able to increase its menu from five to more than 30 tests performed on its low cost, point-of-care diagnostic testing platform, BTIG analyst Mark Massaro said in a research note.

"We believe Lumira is well positioned to win based on test performance, price, global reach, and over time, test menu, where it's planning to launch tests in cardiovascular disease, diabetes, and [sexually transmitted diseases]," Massaro said.

The London-based diagnostics company, which is led by executives who had worked with Alere, now part of Abbott, offers a handheld instrument that can perform antigen, antibody, and molecular testing.

Massaro noted that Lumira has plans to launch a mass screening and home testing system for COVID-19 testing, called Amira, in Q4 2021, which is well equipped to enable the commercialization of tests in low-income countries. While its revenue is now derived primarily from antigen-based COVID-19 testing, the firm has also developed qStar, a non-PCR enzyme-based system for rapid molecular testing, he noted.

Though Lumira expects 2024 revenues of between $1 billion and $1.25 billion, BTIG initiated coverage with a 2024 estimate of $619 million.

Last month, the point-of-care testing company went public on the Nasdaq at $9.94 per share after announcing the closing of its previously announced merger with CA Healthcare Acquisition, a special purpose acquisition company.

The Scan

Looking for Omicron

NPR reports that SARS-CoV-2 testing in the US has gotten better but also that some experts say more needs to be done to better track the Omicron variant.

Holmes Alleges Abuse

The Associated Press reports that Theranos' Elizabeth Holmes has testified at her wire fraud trial that her business and romantic partner abused her.

Bit More Diverse, But More to Do

While Black and Hispanic patients are more likely to participate in cancer clinical trials than previously, they are still underrepresented, according to US News & World Report.

PNAS Papers on Yeast Gene Silencing, Zika Virus Inhibition, Immunoglobulin Hypermutation

In PNAS this week: gene silencing in Saccharomyces cerevisiae, possible neuroprotective role for SHFL in a mouse model of Zika virus infection, and more.